Policy of pharmacological treatment of ulcerative colitis (a review of foreign literature)

Cite item

Full Text

About the authors

V G Rumyanlsev


  1. Sutherland L. R., May G. R., Shaffer E. A. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann. Intern. Med. 1993; 118: 540-549.
  2. Hanauer S. В., Meyers S., Sachar D. B. The pharmacology of antiinflammatory drugs in inflammatory bowel disease. In: Kirsner J. В., Shorter R. G., ed. Inflammatory bowel disease. 4-th ed. Baltimore: Williams & Wilkins; 1995. 643-663.
  3. Dickinson R. J., King A., Wight D. G. D. et al. Is continuous sulfasalazine necessory in the management of patients with ulcerative colitis? Results of preliminary study. Dis. Colon Rectum 1985; 28: 929-930.
  4. Armstrong G., Montrose M. H. 5-aminosalicyiate retention in the murine colonic mucosa varys among cell types. Gastroenterology 1998; 114(4, pt 2): G3784.
  5. Gionchetti P., Rizzello F., Venturi A. et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis. Colon Rectum 1998; 41(1): 93-97.
  6. Frieri G., Pimpo M. Т., Palumbo G. С. et al. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment. Pharmacol. Ther. 1999; 13(11): 1413-1417.
  7. Fiedmann L. S., Rither J. M., Kirkhan S. E. et al. 5-aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. Am. J. Gastroenterol. 1986; 6: 412- 418.
  8. Lucidarme D., Marteau P., Foncault M. et al. Efficacy and tolerance of mesalazine suppositories vs. hydrocortisone foam in proctitis. Aliment. Pharmacol. Ther. 1997; 11(2): 335-340.
  9. Hanauer S. B. Dose-ranging study of mesalamine (pentasa) enemas in the treatment of acute ulcerative proctosygmoiditis: Results of a multicentered placebo-controlled trial. 1BD 1998; 4: 79-83.
  10. Cohen R. D., Woseth D. M., Hanauer S. B. Meta-analysis 1: Treatment modalities in left-sided ulcerative colitis. Gastroenterology 1998; 114(4, pt 2): G 3907.
  11. Marshall J. K, Irvine E. J. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment. Pharmacol. Ther. 1995; 9: 23-300.
  12. Marshall J. K., Irvine E. J. Rectal corticosteroids vs. alternative treatment in ulcerative colitis: a meta-analysis. Gut 1997; 40: 775-781.
  13. Safdi M., DeMicco M., Sninsky С. et al. A double blind comparison of oral vs. rectal mesalamine vs. combination therapy in the treatment of distal ulcerative colitis. Am. J. Gastroenterol. 1997; 92: 1867-1871.
  14. D'Albasio G., Pacini F., Camarri E. et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative proctitis: a randomized double-blind study. Ibid. 1143-1147.
  15. Powell-Tuck J., Brown R., Lennard-Jones J. E. A comparative of oral prednisolone as single or multiple daily doses for active proctocolitis. Scand. J. Gastroenterol. 1987: 13: 833-837.
  16. Truelove S. C., Jewell D. P. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 1067-1070.
  17. Rosenberg W., Ireland A., Jewell D. P. High-dose methylprednisolone in the treatment of active ulcerative colitis. J. Clin. Gastroenterol. 1990; 12:40-41.
  18. Kornbluth A., Salomon P., Sacs H. S. et al. Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. J. Gastroenterol. 1993; 16: 215-218.
  19. Powell-Tuck J., Brown R. L., Chambers T. J., Lennard-Jones J. E. A controlled trial of alternate day prednisolone as a maintenance treatment of ulcerative colitis in remission. Digestion 1981; 22: 263-270.
  20. Lofberg R., Osteigaard-Thomsen O., Langholtz E. et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment. Pharmacol. Ther. 1994; 8: 623-629.
  21. Danish Budesonide Study Group. Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. Scand. J. Gastroenterol. 1991; 26: 1225-1230.
  22. Mulder С. J. J., Fockens P., Meijer J. W. R. et al. Beclomethazone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retension enemas in active ulcerative proctitis. Eur. J. Gastroenterol. Hepatol. 1996; 8(6): 549-553.
  23. Kirk A. P., Lennard-Jones J. E. Controlled trial of azathioprine in chronic ulcerative colitis. Br. Med. J. 1982; 284: 1291.
  24. Adler D. J., Korelitz B. I. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am. J. Gastroenterol. 1990; 85: 717.
  25. George J. et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Ibid. 1996; 91: 1711.
  26. Oren R., Arber N., Odes S. et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110: 1416-1421.
  27. Kozarek R., Bedard С., Patterson D. et al. Cyclosporin use in the precolectomy chronic ulcerative colitis patients: a community experience and its relationship to prospective and controlled clinical trials. Am. J. Gastroenterol. 1995; 90: 2093-2096.
  28. Lemann M., Modigliani R. Acquisitions recentes fans le traitement medicamenteux des maladies inflammatoires de 1'intestin. In: Ruszniewski P., Larrey D., eds. Progres en hepatogastroenterologie. Prescrire en hepato-gastroenterologie. Paris: Doin; 1997.42-75.
  29. Riley S. A., Mani V., Goodman M. J. et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174- 178.
  30. Courtney M. G., Nunes D. P.. Bergin С. F. et al. Colonoscopic but not histological appearances determine likelihood of relapse of ulcerative colitis. Am. J. Gastroenterol. 1991; 86: 246.
  31. Goodman M. W., Eberle D. E., Kuchler L. A., Possum E. A. Microscopic activity predicts relapse in patients with distal ulcerative colitis on 4-amibosalicylic acid enemas. Gastroenterology 1988; 96: A151.
  32. Kruis W., Schutz E., Eric P. et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 1997; 15: 853-858.
  33. Rembacken B. J., Snelling A. M., Hawkey P. M. et al. Nonpathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999; 1(21): 635-639.
  34. Stange E. F., Modigliani К., Репа A. S. et al. European trial of cyclosporine in chronic active Crohn's disease. Gastroenterology 1995; 109: 774-782.
  35. Stange E. F., Riemann J., van Herbay A. et al. Diagnostik and Therapie der Colitis ulcerosa - Ergebnisse einer evidenz basicrtcn Konsensuskonferenz der "Deutschen Gesellschaft fur Verdauungs - and Stoffwechselkrankheiten". Z. Gastroenterol. 2002; 39: 19-72.

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies